4 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 4, 1 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 3 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Neostigmine + Atropine: new trials by email Literature Review of Neostigmine + Atropine trials Research Report on Neostigmine + Atropine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter Sugammadex 2 mg/kg, Neostigmine + Atropine - Neuromuscular Blockade Reversal Agent | Phase 4 | Completed | Cukurova University | 86 | 2026-06-25 | 2026-10-21 |
| Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery Neostigmine + Atropine, Sugammadex - Postoperative Gastrointestinal Dysfunction (POGD), Postoperative Ileus | Phase 3 | Not yet recruiting | Xijing Hospital | 560 | 2026-01-01 | 2025-12-09 |
| Emergence Agitation Neostigmine + Atropine, Sugamadex - Emergence Agitation, Nasal Surgery | Not applicable | Active not recruiting | Ain Shams University | 486 | 2025-10-30 | 2025-11-28 |
| Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade Sugammadex 1 mg/kg, Neostigmine + Atropine - Neuromuscular Blocking Agents, Reversal of Neuromuscular Blockade | Phase 1 / Phase 2 | Recruiting | Universitas Padjadjaran | 60 | 2024-11-05 | 2025-01-28 |
| Sugammadex and Time to Extubation in Ophthalmic Surgery sugammadex, Neostigmine + Atropine - General Anesthesia Using Endotracheal Intubation, Ophthalmologic Surgical Procedure | Completed | China Medical University Hospital | 262 | 2023-08-01 | 2024-10-08 | |
| Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate - Neuromuscular Blockade | Phase 4 | Completed | Merck Sharp & Dohme LLC | 145 | 2019-07-23 | 2025-07-25 |
| Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089) Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate - Neuromuscular Blockade | Phase 4 | Completed | Merck Sharp & Dohme LLC | 288 | 2018-02-12 | 2021-02-05 |
Merck Sharp & Dohme LLC (2) · Ain Shams University (1) · China Medical University Hospital (1) · Cukurova University (1) · Universitas Padjadjaran (1) · Xijing Hospital (1)
Belgium (2) · Denmark (2) · Finland (2) · Turkey (Türkiye) (2) · United States (2) · Australia (1) · Austria (1) · Brazil (1) · France (1) · Germany (1) · Guatemala (1) · Hungary (1) · Indonesia (1) · Malaysia (1) · Mexico (1)
Ersel Gulec, MD (1) · Tini T Maskoen, M.D. (1) · Yi-Ying Chiang, MD (1)
2017 (2)